References
- O’Conner OA. Getting the Facts: Peripheral T-Cell Lymphoma. Lymphoma Research Foundation, July 2009
- Howlader N, Noone AM, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975-2010, Bethesda, MD, National Cancer Institute. Table 19.26, non-Hodgkin lymphoma section. Available at: http://seer.cancer.gov/csr/1975_2009_pops09/browse_csr.php?sectionSEL=19&pageSEL=sect_19_table.26.html [Last accessed 21 February 2014]
- Abouyabis AN, Shenoy PJ, Lechowicz MJ, et al. Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States. Leuk Lymphoma 2008;49:2099-107
- NCCN Guidelines v3.2012. Available at: http://www.nccn.org/professionals/default.aspx [Last accessed October 2012]
- Zinzani PL, Venturini F, Stefoni V, et al. Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol 2010;21:860-3
- Foss FM, Zinzani PL, Vose JM, et al. Peripheral T-cell lymphoma. Blood 2011;117:6756-67
- Savage KJ. Therapies for peripheral T-cell lymphomas. Hematology 2011;(1):515-24
- Howman RA, Prince HM. New drug therapies in peripheral T-cell lymphoma. Expert Rev Anticancer Ther 2011;11:457-72
- Thomas DA, O’Brien S, Cortex J. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood 2004;104:1624-30
- Kruse GB, Amonkar MM, Smith G, et al. Analysis of costs associated with administration of intravenous single-drug therapies in metastatic breast cancer in a U.S. population. J Manag Care Pharm 2008;14:844-57
- Duh MS, Weiner JR, Lefebvre P, et al. Costs associated with intravenous chemotherapy administration in patients with small cell lung cancer: a retrospective claims database analysis. Curr Med Res Opin 2008;24:967-74
- Wong BJ, Cifaldi MA, Roy S, et al. Analysis of drug and administrative costs allowed by U.S. private and public third-party payers for 3 intravenous biologic agents for rheumatoid arthritis. J Managed Care Pharm 2011;17:313-20
- Vose JM, Neumann M, Harris ME. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26:4124-30
- Kamata M, Sugaya M, Miyagaki T, et al. A case of CD20-positive peripheral T-cell lymphoma treated with rituximab and multiagent chemotherapy. Int J Dermatol 2014;53(1):e24-6
- Kim P. Cost of cancer care: the patient perspective. J Clin Oncol 2007;25:228-32
- Weingart SN, Brown E, Bach PB, et al. NCCN Task Force Report: oral chemotherapy. J Natl Compr Canc Netw 2008;6(Suppl 3):S1-14